

Peptic Ulcer - Pipeline Insight, 2021

<https://marketpublishers.com/r/PB79C6AE025EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PB79C6AE025EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Peptic Ulcer - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Peptic Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Peptic Ulcer Understanding

Peptic Ulcer: Overview

A peptic ulcer is an open sore or raw area in the lining of the stomach or intestine. There are two types of peptic ulcers: Gastric ulcer -- occurs in the stomach and Duodenal ulcer -- occurs in the first part of the small intestine. Normally, the lining of the stomach and small intestines can protect itself against strong stomach acids. Most ulcers occur in the first layer of the inner lining. A hole in the stomach or duodenum is called a perforation. This is a medical emergency. The most common cause of ulcers is infection of the stomach by bacteria called *Helicobacter pylori* (H pylori). Most people with peptic ulcers have these bacteria living in their digestive tract. Yet, many people who have these bacteria in their stomach do not develop an ulcer.

'Peptic Ulcer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Peptic Ulcer pipeline landscape is provided which includes the disease overview and Peptic Ulcer treatment guidelines. The assessment part of the report embraces, in depth Peptic Ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peptic Ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peptic Ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Peptic Ulcer.

Peptic Ulcer Emerging Drugs Chapters

This segment of the Peptic Ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peptic Ulcer Emerging Drugs

Fexuprazan: Daewoong Pharmaceutical

Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which reversibly blocks the proton pump that secretes gastric acids located in the canalicular membrane. It is a next-generation of proton pump inhibitors (PPI), which are widely used for gastroesophageal reflux disease (GERD). The drug is currently in phase III stage of clinical trial evaluation to treat peptic ulcers.

KFP-H008: Jiangsu Carephar pharmaceuticals

KFP-H008 is a Potassium-competitive acid blocker being developed by Jiangsu

Carephar pharmaceuticals. Currently, it is in Phase III stage of clinical trial evaluation to treat Duodenal ulcer.

Further product details are provided in the report.....

Peptic Ulcer: Therapeutic Assessment

This segment of the report provides insights about the different Peptic Ulcer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peptic Ulcer

There are approx. 8+ key companies which are developing the therapies for Peptic Ulcer. The companies which have their Peptic Ulcer drug candidates in the most advanced stage, i.e. phase III include, Daewoong Pharmaceutical.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Peptic Ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peptic Ulcer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peptic Ulcer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peptic Ulcer drugs.

Peptic Ulcer Report Insights

Peptic Ulcer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Peptic Ulcer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Peptic Ulcer drugs?

How many Peptic Ulcer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peptic Ulcer?

What are the key collaborations (Industry–Industry, Industry–Academia),

Mergers and acquisitions, licensing activities related to the Peptic Ulcer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Peptic Ulcer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Daewoong Pharmaceutical

HK inno.N Corporation

PharmaKing

Recce Pharmaceuticals

Sequella Inc

Shandong Luoxin Pharmaceutical

RaQualia Pharma

Sihuan Pharmaceutical Holdings Group

Sinil Pharmaceutical

Key Products

Fexuprazan

Tegoprazan

PMK S005

R435

SQ109

Anaprazole

SI-001002

Contents

Introduction

Executive Summary

Peptic Ulcer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Peptic Ulcer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Peptic Ulcer companies' collaborations, Licensing, Acquisition -Deal Value Trends

Peptic Ulcer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Fexuprazan: Daewoong Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

PMK S005: PharmaKing

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

- Comparative Analysis

KFP H009: Jiangsu Carephar Pharmaceutical

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report

Inactive Products

- Comparative Analysis

Peptic Ulcer Key Companies

Peptic Ulcer Key Products

Peptic Ulcer- Unmet Needs

Peptic Ulcer- Market Drivers and Barriers

Peptic Ulcer- Future Perspectives and Conclusion

Peptic Ulcer Analyst Views

Peptic Ulcer Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Peptic Ulcer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Peptic Ulcer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Peptic Ulcer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PB79C6AE025EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB79C6AE025EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970